Changchun High-Tech Industry (Group) (000661) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥6.64 billion, up 7.63% year-over-year; net profit attributable to shareholders was ¥1.72 billion, down 20.40% year-over-year.

• Biopharma, vaccines, and TCM remained core, with real estate contributing 6.87% of revenue, up 372.45% year-over-year.

• R&D investment increased 10.18% to ¥1.14 billion; several new drugs and vaccines advanced in clinical and regulatory stages.

• International sales grew 267.78% year-over-year, with overseas revenue of ¥85.24 million.

• No interim dividend was declared for the period.

Financial highlights

• Operating income: ¥6.64 billion (+7.63% YoY); net profit attributable: ¥1.72 billion (-20.40% YoY).

• Operating cash flow: ¥1.98 billion (-2.24% YoY); total assets: ¥29.98 billion (-2.47% from year-end 2023).

• Basic EPS: ¥4.28 (-20.30% YoY); ROE: 7.73% (-3.55pp YoY).

• Non-recurring items netted a loss of ¥17.47 million.

Outlook and guidance

• The company will continue to focus on innovation-driven growth, international expansion, and product pipeline enrichment.

• Emphasis on compliance, risk management, and adapting to evolving healthcare policies.

• No interim dividend; focus remains on long-term value and shareholder returns via future profit distribution and buybacks.